National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Front Matter." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
III
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Committee on Issues and Priorities for New Vaccine Development

SAMUEL L.KATZ (chair),

Department of Pediatrics, Duke University Medical Center

A.JOHN BEALE,

Wellcome Research Laboratories, United Kingdom

MARSHALL H.BECKER,

Department of Health Behavior, University of Michigan, Ann Arbor

JAMES CHIN,

Department of Health Services, State of California Health and Welfare Agency, Berkeley

PURNELL W.CHOPPIN, Professor of Virology,

Rockefeller University

THEODORE C.EICKHOFF,

Department of Internal Medicine, Presbyterian/St. Luke’s Medical Center, Denver

FRANCIS A.ENNIS,

Department of Medicine and Molecular Genetics, University of Massachusetts Medical Center, Worcester

HARVEY V.FINEBERG,

Institute for Health Research, Harvard School of Public Health

MAURICE R.HILLEMAN,

Merck Institute for Therapeutic Research, Merck Sharp & Dohme Research Laboratories

GERALD T.KEUSCH,

Division of Geographic Medicine, Tufts University

RICHARD F.KINGHAM,

Covington and Burling, Washington, D.C.

BERNARD ROIZMAN,

Department of Microbiology and Biophysics, University of Chicago

HENRY R.SHINEFIELD,

Department of Pediatrics, Kaiser Permanente Medical Group, San Francisco

JANE E.SISK,

Office of Technology Assessment, United States Congress

CLADD E.STEVENS,

Laboratory of Epidemiology, The New York Blood Center

LEROY WALTERS,

Kennedy Institute of Ethics, Georgetown University

MILTON C.WEINSTEIN,

Institute for Health Research, Harvard School of Public Health

See Appendix S for further information on committee members.

Consultants

GENEVIVE A.LOSONSKY,

Department of Pediatrics, Johns Hopkins University Hospital

ARNOLD S.MONTO,

School of Public Health, University of Michigan

B.FRANK POLK,

School of Hygiene and Public Health, Johns Hopkins University

JOHN B.ROBBINS,

National Institute of Child Health and Human Development, National Institutes of Health

DONALD S.SHEPARD,

Institute for Health Research, Harvard School of Public Health

DAVID H.SMITH,

Department of Pediatrics, University of Rochester

Page
III
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)